NDLI: Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease.

Please wait, while we are loading the content...

Association of Fish Consumption-Derived Ratio of Serum n-3 to n-6 Polyunsaturated Fatty Acids and Cardiovascular Risk With the Prevalence of Coronary Artery Disease.

Cardiac diastolic function is impaired at rest and worsens with exercise in otherwise healthy individuals with insulin resistance.

Elevated Concentration of Interferon-Inducible Protein of 10 kD (IP-10) Is Associated With Coronary Atherosclerosis.

Efficacy and safety of ultrafiltration in decompensated heart failure patients with renal insufficiency.

Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease.

Impact of low signal intensity assessed by cine magnetic resonance imaging on detection of poorly viable myocardium in patients with prior myocardial infarction.

Opening of native aortic valve accomplished after left ventricular assist device implantation in patients with insufficient preoperative Beta-blocker treatment.

Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension.

Spontaneous spiral dissection of left internal thoracic artery graft.

Erratum: fulminant type 1 diabetes mellitus and fulminant viral myocarditis.

High Level of von Willebrand Factor in Non-ST Segment Elevation Myocardial Infarction Patients Predicted Cardiovascular Ischemic Events After Off-Pump Coronary Artery Bypass Surgery.

Biventricular pacing with ventricular fusion by intrinsic activation in cardiac resynchronization therapy.

Platelet Glycoprotein IIb/IIIa Inhibitor Tirofiban Ameliorates Cardiac Reperfusion Injury.

Clinical significance of high-sensitivity cardiac troponin T in patients with dilated cardiomyopathy.

Evaluation of right ventricle by speckle tracking and conventional echocardiography in rats with right ventricular heart failure.

Association between left atrial appendage morphology evaluated by trans-esophageal echocardiography and ischemic cerebral stroke in patients with atrial fibrillation.

Improvement of Predictive Value for Thromboembolic Risk by Incorporating Left Atrial Functional Parameters in the CHADS2 and CHA2DS2-VASc Scores.

Clinical implications of increased Nogo-B levels in patients with acute coronary syndromes and stable angina pectoris.

Pathological role of adipose tissue dysfunction in cardio-metabolic disorders.

Pleiotropic Effects of Angiotensin II Receptor Signaling in Cardiovascular Homeostasis and Aging.

Year: 2015 Volume: 56 Issue: 2

Year: 2015 Volume: 56 Issue: 1

Year: 2015 Volume: 56 Issue: Supplementary

Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Masuda, Jun Tanigawa, Takashi Yamada, Tomomi Nishimura, Yuki Sasou, Takashi Nakata, Tomoyuki Sawai, Toshiki Fujimoto, Naoki Dohi, Kaoru Miyahara, Masatoshi Nishikawa, Masakatsu Nakamura, Mashio Ito, Masaaki
Description	Author Affiliation: Masuda J ( Department of Cardiology and Nephrology, Mie University Graduate School of Medicine.)
Abstract	Ezetimibe has been reported to provide significant incremental reduction in low-density-lipoprotein cholesterol (LDL-C) when added to a statin; however, its effect on coronary atherosclerosis has not yet been evaluated in detail. The aim of this study was to investigate the add-on effect of ezetimibe to a statin on coronary atherosclerosis evaluated by intravascular ultrasound (IVUS).In this prospective randomized open-label study, a total of 51 patients with stable coronary artery disease (CAD) requiring percutaneous coronary intervention (PCI) were enrolled, and assigned to a combination group (n = 26, rosuvastatin 5 mg/day + ezetimibe 10 mg/day) or a monotherapy group (n = 25, rosuvastatin 5 mg/day). Volumetric IVUS analyses were performed at baseline and 6 months after the treatment for a non-PCI site. LDL-C level was significantly reduced in the combination group (-55.8%) versus that in the monotherapy group (-36.8%; P = 0.004). The percent change in plaque volume (PV), the primary endpoint, appeared to decrease more effectively in the combination group compared with the monotherapy group (-13.2% versus -3.1%, respectively, P = 0.050). Moreover, there was a significant group × time interaction in the effects of the two treatments on PV (P = 0.021), indicating the regressive effect of the combination therapy on PV was greater than that of monotherapy for subtly different values of baseline PV in the two treatment groups. Moreover, percent change in PV showed positive correlations with percent change of LDL-C (r = 0.384, P = 0.015).Intensive lipid-lowering therapy with ezetimibe added to usual-dose statin may provide significant incremental reduction in coronary plaques compared with usual-dose statin monotherapy.
File Format	HTM / HTML
ISSN	13492365
e-ISSN	13493299
Journal	International Heart Journal
Issue Number	3
Volume Number	56
Language	English
Publisher	International Heart Journal Association
Publisher Date	2015-05-13
Publisher Place	Japan
Access Restriction	Open
Subject Keyword	Discipline Cardiology Anticholesteremic Agents Administration & Dosage Azetidines Coronary Artery Disease Drug Therapy Fluorobenzenes Pyrimidines Sulfonamides Pathology Drug Therapy, Combination Ezetimibe Hydroxymethylglutaryl-coa Reductase Inhibitors Prospective Studies Rosuvastatin Calcium Ultrasonography, Interventional Comparative Study Randomized Controlled Trial Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Cardiology and Cardiovascular Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Use of once-weekly statin in combination with ezetimibe in a patient with mitochondrial disease.

HDL cholesterol and residual risk of first cardiovascular events.

Rosuvastatin-induced pemphigoid.

A rosuvastatin klinikai jelentosége napjaink lipidológiai gyógyszerelésében.

Rosuvastatin and progression of atherosclerosis.

Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.

Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.

Statin, the black box.

Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study.

Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease.

Similar Documents

Use of once-weekly statin in combination with ezetimibe in a patient with mitochondrial disease.

HDL cholesterol and residual risk of first cardiovascular events.

Rosuvastatin-induced pemphigoid.

A rosuvastatin klinikai jelentosége napjaink lipidológiai gyógyszerelésében.

Rosuvastatin and progression of atherosclerosis.

Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.

Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.

Statin, the black box.

Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study.

Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease.